Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 22 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

14%

3 trials in Phase 3/4

Results Transparency

38%

3 of 8 completed with results

Key Signals

3 with results100% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (6)
Early P 1 (2)
P 1 (3)
P 2 (1)
P 3 (2)
P 4 (1)

Trial Status

Completed8
Recruiting6
Not Yet Recruiting4
Unknown2
Active Not Recruiting2

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 8 completed trials

Clinical Trials (22)

Showing 20 of 20 trials
NCT07465718Phase 3Not Yet RecruitingPrimary

Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.

NCT07462026CompletedPrimary

Exchangeable and Relative Exchangeable Copper as an Alternative to 24-Hour Urinary Copper in Wilson's Disease Monitoring

NCT04537377Phase 1Active Not RecruitingPrimary

A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease

NCT07240896Early Phase 1RecruitingPrimary

A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)

NCT07010575Phase 2CompletedPrimary

Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride

NCT05493605Not ApplicableRecruitingPrimary

Cardiac Involvement in Wilson's Disease

NCT05183165Not ApplicableRecruitingPrimary

Description of the Copper Concentration in Breast Milk in Women Treated for Wilson's Disease

NCT07241832Not Yet RecruitingPrimary

Multifaceted Assessment of Patients With Wilson's Disease in a Low-Resource Setting in Upper Egypt: Service Integration, Psychosocial Burden, Dietary Practices, and the Geo-Spatial Disease Map

NCT07208565Not Yet RecruitingPrimary

Endocrine Dysfunction in Pediatric Wilson's Disease

NCT02552628Not ApplicableCompleted

WILSTIM - DBS (WILson STIMulation - Deep Brain Stimulation)

NCT06128954Phase 1CompletedPrimary

Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily).

NCT05239858RecruitingPrimary

International Wilson's Disease Patient Registry (iWilson Registry)

NCT02252380Not ApplicableActive Not Recruiting

ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders

NCT00212355Phase 3CompletedPrimary

Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan.

NCT05305872Phase 4RecruitingPrimary

Gandouling in the Treatment of Wilson's Disease

NCT06051734Not Yet Recruiting

Early Detection of Cardiac Affection in Patients of Wilson's Disease

NCT02702765Not ApplicableCompletedPrimary

sCD163 and sMR in Wilsons Disease - Associations With Disease Severity and Fibrosis

NCT04212195UnknownPrimary

Cohort Research on Wilson's Disease

NCT04012658RecruitingPrimary

A Registered Cohort Study on Wilson's Disease

NCT03957720Early Phase 1UnknownPrimary

The Individual Therapy for Patients With Wilson's Disease

Scroll to load more

Research Network

Activity Timeline